CYBN - צמיחת הכנסות משנה לשנה ב-12 החודשים האחרונים Cybin

Cybin Inc. (CYBN) is developing psychedelics within the North American legal framework, which eliminates sanction threats. The relative change in trailing twelve-month revenue compared to the same period last year demonstrates scaling dynamics, where 0.00 represents the latest metric reading. While prospects are tied to establishing a revolutionary psychiatric standard, the lack of commercial products and the costs associated with FDA trials create significant risks for capital.
פילוחי נתונים אנליטיים מרוכזים עבור cybin.com (CYBN)

Cybin Inc. specializes in developing innovative psychedelic drugs for depression therapy using artificial intelligence. By analyzing the trailing twelve-month (TTM) sales growth rate, an investor assesses revenue dynamics over the last twelve months relative to the previous year, which helps identify the sustainability of business expansion or the risk of capital stagnation during the development of new drug formulas.